GlassScriptPhysician profile
Thomas R Mcminn
NPI 1316947344
$28,622.24
in general payments reported to CMS, 2019-2025
27 companies · $4,686 in 2025
The $4,686 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,194 · 2021: $876 · 2022: $462 · 2023: $588 · 2024: $4,343 · 2025: $4,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,195 · Food and Beverage: $3,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,195.00 |
| Food and Beverage | $3,422.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $25,032.54 | 2019-2025 | Cardiomems, Ultreon, Coroflow |
| Abiomed | $867.20 | 2019-2024 | Impella |
| Medtronic, INC. | $443.01 | 2021-2025 | Corevalve Evolut R |
| Actelion Pharmaceuticals US, INC. | $410.06 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $247.32 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $192.55 | 2021-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $154.32 | 2024-2025 | Ozempic |
| Pfizer INC. | $147.81 | 2024-2025 | |
| Biotronik INC. | $131.49 | 2019 | |
| Cvrx, INC. | $125.96 | 2023 | Barostim Neo System |
| Acist Medical Systems, INC. | $109.02 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.50 | 2019-2024 | Lifevest |
| Amgen INC. | $104.57 | 2019-2025 | Repatha, Repatha |
| Shockwave Medical, INC | $82.14 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $67.92 | 2019-2024 | Watchman |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $55.29 | 2023 | Optimizer |
| Terumo Medical Corporation | $45.68 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $45.48 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $42.99 | 2021-2022 | |
| Baxter Healthcare | $36.86 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $33.42 | 2019-2022 | |
| Chiesi USA, INC. | $28.26 | 2020-2021 | |
| United Therapeutics Corporation | $28.15 | 2025 | Tyvaso |
| Medtronic Vascular, INC. | $24.46 | 2019 | |
| Atricure, INC. | $23.87 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.80 | 2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcminn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.